© 2020 MJH Life Sciences and Ophthalmology Times. All rights reserved.
ASRS
Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD (ASRS 2020)
August 04, 2020
Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."
Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation (ASRS 2020)
August 03, 2020
Daniel F. Kiernan, MD, FCS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."
How one surgeon is integrating recent retina advances in COVID-19 (ASRS 2020)
August 02, 2020
S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment
Diabetic retinopathy progression in anti-VEGF versus FA implant (ASRS 2020)
August 01, 2020
Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.
AsclepiX lead candidate holds potential for wet AMD, DME, RVO (ASRS 2020)
July 31, 2020
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Alcon showcases latest retina innovations, data (ASRS 2020)
July 30, 2020
ASRS 2020: Josh Anderson speaks on the highlights from Alcon, including new data on the performance benefits of the Hypervit dual blade 20,000 cpm probe and the launch of the NGENUITY 1.4 upgrade.
What Aviceda’s lead candidate AVD-104 may mean for dry AMD (ASRS 2020)
July 30, 2020
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.
Evaluating 3-year-recurrence rate in non-infectious posterior segment veitis post-FAi
July 29, 2020
Dilraj Grewal, MD, associate professor of ophthalmology at Duke Eye Center/ director of grading at the Duke Reading Center, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during the virtual 2020 ASRS meeting.
PDS with ranibizumab signals paradigm shift in treatment of nAMD
July 28, 2020
ASRS 2020 coverage: Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Protocol T Extension Study shows long-term visual declines in DME eyes
July 28, 2020
ASRS 2020 coverage: The results of the Protocol T Extension Study underscore the need for methods to improve long-term visual gains in eyes with diabetic macular edema, according to Dante Pieramici, MD,on behalf of the DRCR Retina Network.